The pharmaceutical promotional landscape is changing, and Medical Review teams should be paying attention.
In September 2025, FDA announced a significant shift in its approach to prescription drug promotion, signaling more aggressive surveillance and enforcement of potentially false or misleading advertising. The Agency simultaneously issued a broad communication to pharmaceutical companies directing them to review promotional materials for compliance and announced increased attention to digital and social media promotion.
For Medical Review professionals, the significance of these announcements extends beyond an increase in enforcement activity. It highlights an important reality: as pharmaceutical communication becomes faster, more diverse, and more complex, strong scientific review becomes increasingly important.
A Changing Promotional Environment
The fundamentals of compliant pharmaceutical promotion have not changed. Claims must still be accurate, appropriately supported, consistent with applicable requirements, and presented in a manner that is not misleading.
What has changed is the environment in which teams must apply those principles.
Today's promotional ecosystem extends well beyond traditional sales aids and advertisements. Companies communicate through social media, search advertising, video, podcasts, digital platforms, third-party programs, executive interviews, and other rapidly evolving channels.
FDA's recent enforcement activity illustrates this breadth. The Agency has raised concerns around risk presentation, omission of material information, promotional communications appearing in search engine results, online videos, and company representatives participating in media programming.
Therefore, the question is no longer whether promotional materials are adequately reviewed; it is whether companies have evolved their Medical, Legal, and Regulatory review model to meet the ways in which they communicate.
Medical Review's Role Is Becoming More Important
In this environment, companies should not position Medical Review solely as a final checkpoint before releasing content but as an integral part of the entire process.
Experienced Medical Reviewers bring scientific judgment to increasingly nuanced questions: Does the evidence adequately support the claim? Does the presentation accurately reflect the strength and limitations of the data? Could technically accurate information nevertheless create an unsupported scientific impression when viewed in context? Is the piece minimizing or omitting important information necessary to understand the communication?
These questions become particularly important as organizations seek to communicate increasingly complex science through shorter, faster, and more dynamic channels.
The strongest Medical Reviews do more than identify what a promotional piece cannot say. Used well, they help organizations understand how to accurately, responsibly, and effectively communicate meaningful scientific information.
Preparing for What's Next
FDA has also indicated that technology, including AI-enabled tools, will play a growing role in its surveillance of pharmaceutical advertising. At the same time, pharmaceutical organizations themselves are adopting new technologies to develop, personalize, and distribute content at greater speed and scale.
That combination could fundamentally alter the Medical Review environment.
More content, a growing number of channels, faster content generation, and increased regulatory surveillance may place new demands on organizations whose Medical Review models were designed for a different promotional landscape.
Now is the time for Medical Review leaders to ask:
• Are we reviewing product-related assets in all channels, not solely in traditional ones?
• Do our reviewers have the scientific expertise, judgment, and experience required to evaluate increasingly complex claims and data?
• Are our review processes capable of maintaining quality as content volume and speed increase?
• Do we have sufficient review capacity during launches, label changes, major congresses, and other periods of increased activity?
• Are we preparing our reviewers for emerging technologies and new forms of pharmaceutical communication?
The Opportunity for Medical Review
Greater regulatory scrutiny does not need to mean slower communication.
In fact, this moment presents an opportunity to strengthen Medical Review as a core competency and one that benefits patients and organizations while helping cross-functional teams confidently communicate important scientific information.
The promotional environment will remain fluid. Technology will accelerate content creation. Communication channels will continue to expand. Regulatory expectations and enforcement priorities will shift ever more in response.
Medical Review Must Evolve With These Changes.
At Canopy Life Sciences, we believe the future of Medical Review lies in combining deep scientific expertise, experienced reviewer judgment, scalable support, and emerging technology to help organizations keep pace with an increasingly complex promotional environment.
The goal of great Medical Review shouldn’t be simply to identify risk. It should be to help organizations holistically communicate science responsibly, accurately, and effectively.
